Norbert Gattermann

15.7k total citations · 1 hit paper
256 papers, 7.2k citations indexed

About

Norbert Gattermann is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Norbert Gattermann has authored 256 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Hematology, 139 papers in Genetics and 54 papers in Molecular Biology. Recurrent topics in Norbert Gattermann's work include Acute Myeloid Leukemia Research (152 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Chronic Lymphocytic Leukemia Research (54 papers). Norbert Gattermann is often cited by papers focused on Acute Myeloid Leukemia Research (152 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (56 papers) and Chronic Lymphocytic Leukemia Research (54 papers). Norbert Gattermann collaborates with scholars based in Germany, United States and Italy. Norbert Gattermann's co-authors include Ulrich Germing, Rainer Haas, Corinna Strupp, Ulrich Germing, Wolfgang Schneider, Carlo Aul, Manuel Aivado, Barbara Hildebrandt, Andreas Hochhaus and Francis J. Giles and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Norbert Gattermann

240 papers receiving 7.0k citations

Hit Papers

Nilotinib (formerly AMN107), a highly selective BCR-ABL t... 2007 2026 2013 2019 2007 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    2007 540 citations Francis J. Giles, Norbert Gattermann et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Norbert Gattermann Germany 44 5.6k 3.7k 2.1k 1.1k 688 256 7.2k
Luca Malcovati Italy 47 5.9k 1.1× 3.8k 1.0× 2.1k 1.0× 396 0.4× 574 0.8× 187 7.5k
Rosangela Invernizzi Italy 31 3.7k 0.7× 2.4k 0.6× 1.5k 0.7× 297 0.3× 584 0.8× 157 5.2k
Mary Frances McMullin United Kingdom 43 4.2k 0.7× 4.4k 1.2× 3.6k 1.7× 1.5k 1.3× 664 1.0× 215 7.5k
Philippe Rousselot France 46 4.7k 0.8× 2.7k 0.7× 1.8k 0.8× 1.7k 1.5× 1.3k 1.8× 181 6.8k
Paresh Vyas United Kingdom 52 5.1k 0.9× 1.8k 0.5× 4.4k 2.1× 305 0.3× 1.3k 1.9× 235 9.4k
Markus Schaich Germany 36 4.5k 0.8× 1.8k 0.5× 2.1k 1.0× 153 0.1× 1.3k 1.9× 116 6.1k
Jason Gotlib United States 51 5.3k 0.9× 5.0k 1.3× 4.0k 1.9× 4.0k 3.6× 1.3k 1.8× 297 11.0k
David Bowen United Kingdom 36 4.4k 0.8× 1.7k 0.5× 2.1k 1.0× 105 0.1× 500 0.7× 132 5.4k
Steffen Koschmieder Germany 37 2.4k 0.4× 1.7k 0.5× 2.8k 1.3× 729 0.7× 730 1.1× 222 5.2k
Marı́a José Calasanz Spain 43 2.2k 0.4× 1.1k 0.3× 3.0k 1.4× 271 0.2× 866 1.3× 153 5.1k

Countries citing papers authored by Norbert Gattermann

Since Specialization
Citations

This map shows the geographic impact of Norbert Gattermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Gattermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Gattermann more than expected).

Fields of papers citing papers by Norbert Gattermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Gattermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Gattermann. The network helps show where Norbert Gattermann may publish in the future.

Co-authorship network of co-authors of Norbert Gattermann

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Gattermann. A scholar is included among the top collaborators of Norbert Gattermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Gattermann. Norbert Gattermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nachtkamp, Kathrin, et al.. (2024). Validation of a novel algorithm with a high specificity in ruling out MDS. International Journal of Laboratory Hematology. 46(3). 510–514. 2 indexed citations
3.
Nachtkamp, Kathrin, et al.. (2022). Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS). Cancers. 14(8). 1941–1941. 10 indexed citations
4.
Radich, Jerald P., Andreas Hochhaus, Tamás Masszi, et al.. (2021). Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 35(5). 1344–1355. 47 indexed citations
5.
Wagenmann, Martin, et al.. (2021). A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells. Molecular Therapy — Oncolytics. 23. 534–546. 16 indexed citations
6.
Germing, Ulrich, Thomas Schroeder, Jennifer Kaivers, et al.. (2019). Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Review of Hematology. 12(10). 893–908. 14 indexed citations
7.
Gattermann, Norbert, et al.. (2018). Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int‐1‐risk MDS patients: Results of the phase II KALLISTO trial. European Journal Of Haematology. 101(2). 208–215. 3 indexed citations
8.
9.
Kuendgen, A., Catharina Müller‐Thomas, Michael Lauseker, et al.. (2013). Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine. Blood. 122(21). 2757–2757. 2 indexed citations
10.
Coutre, Philipp D. le, Jörge E. Cortes, Francis J. Giles, et al.. (2012). Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 27(4). 907–913. 16 indexed citations
11.
Gattermann, Norbert. (2012). Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS. Current Pharmaceutical Design. 18(22). 3222–3234. 11 indexed citations
12.
Schildgen, Verena, Michael Wulfert, & Norbert Gattermann. (2011). Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Experimental Hematology. 39(6). 666–675.e1. 24 indexed citations
13.
Kuendgen, A., Gesine Bug, Oliver G. Ottmann, et al.. (2011). Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clinical Epigenetics. 2(2). 389–399. 29 indexed citations
14.
Aul, C., Ulrich Germing, Norbert Gattermann, D. Söhngen, & A. Heyll. (2008). Prognostische Bedeutung der Serum-Thymidinkinase beim myelodysplastischen Syndrom. DMW - Deutsche Medizinische Wochenschrift. 121(37). 1113–1118. 1 indexed citations
15.
Knipp, Sabine, Norbert Gattermann, M Schapira, H Käferstein, & Ulrich Germing. (2007). Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leukemia Research. 31(11). 1585–1587. 24 indexed citations
16.
Kronenwett, Ralf, Ulrich Steidl, Frank Neumann, et al.. (2005). Distinct molecular phenotype of malignant CD34+ hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 24(34). 5313–5324. 39 indexed citations
17.
Loh, Mignon L., Simone Martinelli, Viviana Cordeddu, et al.. (2004). Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research. 29(4). 459–462. 49 indexed citations
18.
Knipp, Sabine, Barbara Hildebrandt, Aristoteles Giagounidis, et al.. (2004). Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.. Blood. 104(11). 72–72. 6 indexed citations
19.
Gattermann, Norbert, et al.. (2004). Severe Impairment of Nucleotide Synthesis Through Inhibition of Mitochondrial Respiration. Nucleosides Nucleotides & Nucleic Acids. 23(8-9). 1275–1279. 43 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luca Malcovati Breakdown of academic impact, for papers by Rosangela Invernizzi Breakdown of academic impact, for papers by Mary Frances McMullin Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Paresh Vyas Breakdown of academic impact, for papers by Markus Schaich Breakdown of academic impact, for papers by Jason Gotlib Breakdown of academic impact, for papers by David Bowen Breakdown of academic impact, for papers by Steffen Koschmieder Breakdown of academic impact, for papers by Marı́a José Calasanz
Rankless by CCL
2026